• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 424B3 filed by Evogene Ltd

    2/12/25 4:03:39 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials
    Get the next $EVGN alert in real time by email
    424B3 1 zk2532714.htm 424B3


    Filed Pursuant to Rule 424(b)(3)
    Registration No. 333-282218
     
    PROSPECTUS SUPPLEMENT NO. 3
    (to Prospectus dated September 27, 2024)
    3,384,616 Ordinary Shares
     
    This Prospectus Supplement No. 3 updates, amends, and supplements the prospectus dated September 27, 2024 (as amended and supplemented, the “Prospectus”), which forms a part of our Registration Statement on Form F-1 (Registration No. 333- 282218). Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the Prospectus.
     
    This prospectus supplement is being filed to update, amend, and supplement the information in the Prospectus, with respect to the results of the special general meeting of shareholders, included in our Report of Foreign Private Issuer on Form 6-K furnished to the Securities and Exchange Commission on February 12, 2025.
     
    This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference.
     
    As of the date of this Prospectus, our ordinary shares are listed and trade on the Nasdaq Capital Market under the symbol “EVGN”. The last reported sale price of our ordinary shares on February 11, 2025, was $1.49 per share.
     
    Investing in our ordinary shares is highly speculative and involves a high degree of risk. See “Risk Factors” beginning on page 8 of the Prospectus for a discussion of information that should be considered in connection with an investment in our ordinary shares, as well as the risks described under the heading “Item 3 Key Information – D. Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2023, which we filed with the Securities and Exchange Commission on March 28, 2024, and in other documents incorporated by reference into the Prospectus, and under similar headings in any amendment or supplements to the Prospectus.
     
    Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved these securities, or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.
     
    The date of this prospectus supplement is February 12, 2025
     

     
    UNITED STATES
     SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    FORM 6-K
     
    REPORT OF FOREIGN PRIVATE ISSUER
    PURSUANT TO RULE 13a-16 OR 15d-16 OF
    THE SECURITIES EXCHANGE ACT OF 1934
     
    For the month of February 2025
     
    Commission File Number 001-36187

    EVOGENE LTD.
      (Translation of Registrant’s Name into English)
     
    13 Gad Feinstein Street, Park Rehovot, Rehovot
    7638517, Israel
      (Address of principal executive offices)
     
    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
     
    Form 20-F ☒  Form 40-F ☐ 
     


    CONTENTS
     
    Evogene Ltd. (the “Registrant” or the “Company”) hereby announces that the shareholders of the Company approved the proposal brought before the special general meeting of shareholders held on February 12, 2025 (following a one-week adjournment from the original meeting date) (the “Meeting”), by the respective requisite majority in accordance with the Israeli Companies Law, 5759-1999, and the Company’s articles of association, as described in the Proxy Statement which was attached as Exhibit 99.2 to the Company’s Report of Foreign Private Issuer on Form 6-K, furnished to the Securities and Exchange Commission (“SEC”), on December 30, 2024, and sent in connection with the Meeting.

    The contents of this Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) is incorporated by reference in the registration statements on Form F-3 (SEC File No. 333-277565), and Form S-8 (SEC File Nos. 333-193788, 333-201443, 333-203856 and 333-259215) of the Company, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
     

     
    SIGNATURE
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
     



    Date: February 12, 2025
     
    EVOGENE LTD.
    (Registrant)

    By: /s/ Yaron Eldad
    ——————————————
    Yaron Eldad
    Chief Financial Officer
         



     

     
    Get the next $EVGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EVGN

    DatePrice TargetRatingAnalyst
    11/24/2021$8.00 → $7.00Outperform
    RBC Capital
    10/8/2021$7.00Buy
    ROTH Capital
    8/23/2021$8.00Outperform
    RBC Capital
    7/29/2021$10.00Buy
    Aegis Capital
    More analyst ratings

    $EVGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Evogene Schedules First Quarter 2025 Financial Results Release

      Zoom conference call scheduled for May 21, 2025, 9:00 AM ET REHOVOT, Israel, May 8, 2025 /PRNewswire/ -- May 8, 2025 - Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Wednesday, May 21, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance: https://www.veidan-conferenceing.com/evogene The entire conference will be available online on the company's website a fe

      5/8/25 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio

      Lavie Bio improves agriculture productivity and sustainability through microbiome-based ag-biological products REHOVOT, Israel, April 21, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN) a leading computational biology company focused on revolutionizing life-science-based product discovery and development, today announced the signing of a definitive agreement under which ICL, will acquire the majority of activity of Evogene's subsidiary, Lavie Bio Ltd. As part of the agreement, ICL will also acquire Evogene's MicroBoost AI for AG platform.     The transaction is expected to close during the second quarter of 2025, subject to the fulfillment of customary closing conditions. Lavie

      4/21/25 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • Evogene Reports Fourth Quarter and Full Year 2024 Financial Results

      Conference call and webcast: today, March 6, 2025, 9:00 am ET Financial Highlights: In the year 2024, total revenues reached approximately $8.5 million compared to approximately $5.6 million in the year 2023. The increase in revenues is mainly due to increase in AgPlenus' revenues from its collaboration with Bayer and an increase in Casterra's seed sales.In Q4 2024, total revenues reached approximately $1.6 million compared to approximately $0.6 million in Q4 2023. The increase in revenues is mainly due to the increase in Casterra's seed sales.Revenues in Q4 2024 were originally expected to be higher, however, there was a change in delivery schedule of Casterra's seeds from 2024 to 2025. In

      3/6/25 7:15:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials

    $EVGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025

      Mr. Nir Nirmodi is Replacing Ms. Sarit Firon, who will Continue Serving as a Member of the Board REHOVOT, Israel, March 6, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, today announced the appointment of Mr. Nir Nimrodi as the new Chairperson of the Board, succeeding Ms. Sarit Firon, who has held the position since August 2021. Ms. Firon will continue to serve as a member of the Board. As Evogene progresses toward key milestones across its subsidiaries and programs, Mr. Nimrodi's extensive experience in scaling life sciences businesses and driving growth make

      3/6/25 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • Casterra Appoints New CEO and Expands Team to Drive Growth and Innovation

      Mr. Yoash Zohar, a seasoned ag executive, is joining Casterra as CEO to lead the company's significant operational expansion REHOVOT, Israel, Dec. 19, 2023 /PRNewswire/ -- Casterra Ag Ltd., a subsidiary of Evogene Ltd. ("Evogene") (NASDAQ:EVGN) (TASE: EVGN) and an integrated castor cultivation solution company for the bio-based industries (e.g. biofuels, biopolymers), today announced the appointment of Mr. Yoash Zohar as new CEO, as of January 1, 2024, to lead the company's expansion efforts. Considering Casterra's rapid growth and its continued prospects for development, this nomination aims to strengthen its leadership and positioning in the industry. Casterra entered a new phase in its l

      12/19/23 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • AgPlenus Appoints Dr. Adrian Percy to Its Board of Directors

      REHOVOT, Israel, July 12, 2023 /PRNewswire/ -- AgPlenus Ltd., an innovative company designing novel and safe crop protection products allowing food security for a rapidly growing world population, and a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), is pleased to announce the appointment of Dr. Adrian Percy to its board of directors. Dr. Percy, who also serves as a member of Evogene Ltd.'s board of directors since March 2019, brings a wealth of expertise and a deep commitment to advancing environmentally friendly agricultural technologies. With over 25 years of experience in the agricultural industry, Dr. Adrian Percy strongly advocates for environmentally friendly agricultural and f

      7/12/23 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials

    $EVGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Evogene Ltd

      SC 13G/A - Evogene Ltd. (0001574565) (Subject)

      10/15/24 6:52:26 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • SEC Form SC 13G filed by Evogene Ltd

      SC 13G - Evogene Ltd. (0001574565) (Subject)

      2/14/24 8:30:01 PM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • SEC Form SC 13G/A filed by Evogene Ltd (Amendment)

      SC 13G/A - Evogene Ltd. (0001574565) (Subject)

      2/11/22 12:15:01 PM ET
      $EVGN
      Agricultural Chemicals
      Industrials

    $EVGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RBC Capital reiterated coverage on EverGen Infrastructure with a new price target

      RBC Capital reiterated coverage of EverGen Infrastructure with a rating of Outperform and set a new price target of $7.00 from $8.00 previously

      11/24/21 7:31:39 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • ROTH Capital initiated coverage on Evogene with a new price target

      ROTH Capital initiated coverage of Evogene with a rating of Buy and set a new price target of $7.00

      10/8/21 8:30:09 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • RBC Capital initiated coverage on EverGen Infrastructure Corp. with a new price target

      RBC Capital initiated coverage of EverGen Infrastructure Corp. with a rating of Outperform and set a new price target of $8.00

      8/23/21 11:09:14 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials

    $EVGN
    SEC Filings

    See more
    • SEC Form 6-K filed by Evogene Ltd

      6-K - Evogene Ltd. (0001574565) (Filer)

      4/21/25 7:00:10 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • SEC Form EFFECT filed by Evogene Ltd

      EFFECT - Evogene Ltd. (0001574565) (Filer)

      4/3/25 12:15:13 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • SEC Form POS AM filed by Evogene Ltd

      POS AM - Evogene Ltd. (0001574565) (Filer)

      3/28/25 6:09:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials

    $EVGN
    Financials

    Live finance-specific insights

    See more
    • Evogene Schedules First Quarter 2025 Financial Results Release

      Zoom conference call scheduled for May 21, 2025, 9:00 AM ET REHOVOT, Israel, May 8, 2025 /PRNewswire/ -- May 8, 2025 - Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Wednesday, May 21, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance: https://www.veidan-conferenceing.com/evogene The entire conference will be available online on the company's website a fe

      5/8/25 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • Evogene Reports Fourth Quarter and Full Year 2024 Financial Results

      Conference call and webcast: today, March 6, 2025, 9:00 am ET Financial Highlights: In the year 2024, total revenues reached approximately $8.5 million compared to approximately $5.6 million in the year 2023. The increase in revenues is mainly due to increase in AgPlenus' revenues from its collaboration with Bayer and an increase in Casterra's seed sales.In Q4 2024, total revenues reached approximately $1.6 million compared to approximately $0.6 million in Q4 2023. The increase in revenues is mainly due to the increase in Casterra's seed sales.Revenues in Q4 2024 were originally expected to be higher, however, there was a change in delivery schedule of Casterra's seeds from 2024 to 2025. In

      3/6/25 7:15:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • Evogene Schedules Fourth Quarter 2024 Financial Results Release

      Zoom conference call scheduled for March 6, 2025, 9:00 AM ET REHOVOT, Israel, Feb. 20, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the fourth quarter of 2024, on Thursday, March 6, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance: https://us06web.zoom.us/webinar/register/WN_1cToyoipTfW8X0xtgEqPfw The entire conference will be available online on the company's

      2/20/25 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials